Registry on the EXperience of Extracorporeal CO2 Removal in Intensive Care Units

  • End date
    Jun 25, 2022
  • participants needed
  • sponsor
Updated on 25 January 2021


Investigators will aim to conduct an observational study in order to assess very thoroughly all patients implanted by Extracorporeal carbon dioxide removal (ECCO2R) in 10 critical care units of Paris and its surburb (APHP, Assistance Publique des hpitaux de Paris).

Secondary objectives will be:

  1. to assess efficacy and safety of ECCO2R,
  2. to compare the data issue from the registry to others studies assessing the same population and to other centers and
  3. to compare the different ECCOR devices in terms of efficacy and adverse events.


The registry will be conducted prospectively during 2 years in 10 ICUs of l'APHP on behalf on the CEDIT. The 10 centers are : (1) ICU of l'hpital europen Georges Pompidou, (2) ICU of l'Hpital Louis Mourier, (3) ICU of l'Hpital de Bictre, (4) ICU of GHPS, (5) Respiratory ICU of GHPS, (6) ICU of l'Hpital Lariboisire (7) ICU of l'Hpital Cochin (8) ICU of l'Hpital Saint-Antoine (9)ICU of l'Hpital Henri Mondor and (10) ICU of l'Hpital Tenon.

The primary outcome will be the number of patients implanted by ECCO2R monthly in each center during the 2 years period study.

Secondary outcomes will be ICU-mortality, invasive ventilation duration, non invasive ventilation duration, ICU duration, modalities of ventilation at the ICU discharge, hemorragic complications due to the ECCOR device, thrombotic complications due to ECCO2R device, intravascular hemolysis due to ECCO2R device, duration of ECCO2R, adjunct therapy to ECCO2R and reasons of ECCO2R discontinuation.

Condition Patients With Acute Exacerbation of Chronic Obstructive Pulmonary Disease, Patients With Acute Respiratory Distress Syndrome
Treatment ECCO2R
Clinical Study IdentifierNCT02965079
Last Modified on25 January 2021


Yes No Not Sure

Inclusion Criteria

Is your age greater than or equal to 18 yrs?
Gender: Male or Female
Do you have any of these conditions: Patients With Acute Exacerbation of Chronic Obstructive Pulmonary Disease or Patients With Acute Respiratory Distress Syndrome?
Patients implanted with ECCCO2R

Exclusion Criteria

Contra-indication to ECCO2R
Clear my responses

How to participate?

Step 1 Connect with a site
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact


Phone Email

Please verify that you are not a bot.

Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider


Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 



Reply by • Private

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note